Researchers found that people with Long COVID have significantly more 'zombie cells' (senescent cells) than healthy individuals. These damaged cells stop dividing but refuse to die, releasing inflammatory chemicals that may drive ongoing symptoms like fatigue and brain fog. The study followed 240 patients and found that those with the highest levels of senescent cell markers had the most severe symptoms. This suggests that therapies targeting these cells (senolytics) could potentially reduce Long COVID symptoms.

Scientists discovered that pieces of the COVID virus's spike protein can remain in the gut lining for over two years after infection. In this study of 85 patients with ongoing symptoms, 67% had detectable spike protein in their intestinal tissue. This viral persistence may continuously trigger immune responses, explaining why many Long COVID patients experience digestive issues alongside systemic symptoms like fatigue and brain fog. The finding supports investigating antiviral therapies for Long COVID.

This large study found that the immune system of many Long COVID patients produces antibodies that mistakenly attack the body's own tissues. By testing 450 patients, researchers identified specific patterns of these 'autoantibodies' that can predict which symptoms a person will develop and how severe they will be. Patients with antibodies targeting nerve tissue tended to have more neurological symptoms, while those with antibodies against blood vessel cells had more cardiovascular issues. This could lead to personalized treatment approaches based on each patient's unique immune profile.

Researchers across 12 medical centers found that many Long COVID patients experience reactivation of Epstein-Barr virus (EBV), a common herpesvirus that most people carry dormant. Of 380 patients studied, 58% showed signs of EBV reactivation, and those with higher EBV activity had worse fatigue and cognitive symptoms. This suggests that COVID may weaken immune surveillance, allowing dormant viruses to 'wake up' and contribute to ongoing illness. Antiviral treatments targeting reactivated EBV are now being explored as a potential Long COVID therapy.

This study found that patients with higher levels of mercury and lead in their blood experienced more severe and longer-lasting Long COVID symptoms. Heavy metals increase oxidative stress, which amplifies the inflammatory response already triggered by viral infection. Of 200 patients tested, those in the highest quartile for heavy metal exposure had 2.3x higher inflammatory markers. The researchers suggest that heavy metal detoxification protocols could be a useful complementary approach for certain Long COVID patients, particularly those with known environmental exposures.

In a rigorous clinical trial, researchers showed that a specially formulated probiotic targeting bacterial strains depleted by COVID infection significantly reduced fatigue in Long COVID patients. The 16-week trial with 160 participants found that the probiotic group experienced a 40% reduction in fatigue scores compared to placebo. Gut bacteria play a crucial role in immune regulation and energy metabolism, and restoring the right microbial balance appears to help the body recover from post-viral disruption. The specific strains used included Lactobacillus rhamnosus and Bifidobacterium longum, among others.